Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs

ClinicalTrials.gov ID

NCT07136701

Lead Sponsor

Qilu Hospital of Shandong UniversityOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

600Estimated

Last Update Posted

Aug 13, 2026Actual

Start Date

Aug 31, 2025Actual

Primary Completion Date

Jun 30, 2026Actual

Completion Date

Jul 31, 2027Estimated

Official Title

Study in Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics Between Early- and Late-Onset Pancreatic Neuroendocrine Tumors: A Multicenter Retrospective Study

Brief Summary

The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine tumors (EO-PanNETs) and late-onset pancreatic neuroendocrine tumors (LO-PanNETs).

The main questions it aims to answer are:

Are there distinct clinical, pathological, and metabolic profiles in EO-PanNETs compared with LO-PanNETs? Do EO-PanNETs have different prognostic outcomes compared with LO-PanNETs? Researchers will compare EO-PanNET patients with LO-PanNET patients and with matched nonmalignant controls to assess differences in tumor characteristics and associated metabolic conditions.

Participants will:

Provide retrospective clinical, pathological, and metabolic data from hospital records.

Have survival and recurrence outcomes assessed through follow-up data review.

• Pancreatic Neuroendocine Neoplasms (pNETs)

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• 18 years or older; histopathologically confirmed pancreatic neuroendocrine tumor by surgical resection or biopsy.

Exclusion Criteria:

• Pancreatic neuroendocrine carcinoma; incomplete pathological data; received antitumor treatment prior to presentation; with other malignanies or malignant history.

Observational Model

Cohort

Time Perspective

Retrospective

Lead Sponsor

Qilu Hospital of Shandong UniversityOTHER

Collaborators

China-Japan Friendship HospitalOTHER

The Affiliated Hospital of Qingdao UniversityOTHER

Qianfoshan HospitalOTHER

gaochanghao44@gmail.com+86-17860624903

• Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors

  NCT02586844

  CompletedObservationalUpdated Apr 14, 2022
• A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors

  NCT00745381

  CompletedObservationalUpdated Aug 4, 2020
• Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan

  NCT02102893

  CompletedObservationalUpdated Jul 29, 2022
• CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors

  NCT07429851

  RecruitingObservationalUpdated Feb 24, 2026
• Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients

  NCT03048266

  RecruitingObservationalUpdated May 23, 2019
• Neuroendocrine Tumors - Patient Reported Outcomes

  NCT05064150

  Active, not recruitingObservationalUpdated Aug 20, 2026